De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
In: Journal of Clinical Oncology, Jg. 41 (2023-08-01), Heft 22, S. 3796-3804
Online
academicJournal
Zugriff:
Titel: |
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
|
---|---|
Autor/in / Beteiligte Person: | Harbeck, Nadia ; Nitz, Ulrike A. ; Christgen, Matthias ; Kümmel, Sherko ; Braun, Michael ; Schumacher, Claudia ; Potenberg, Jochem ; Tio, Joke ; Aktas, Bahriye ; Forstbauer, Helmut ; Grischke, Eva-Maria ; Scheffen, Iris ; Malter, Wolfram ; von Schumann, Raquel ; Just, Marianne ; zu Eulenburg, Christine ; Biehl, Claudia ; Kolberg-Liedtke, Cornelia ; Deurloo, Regula ; de Haas, Sanne |
Link: | |
Zeitschrift: | Journal of Clinical Oncology, Jg. 41 (2023-08-01), Heft 22, S. 3796-3804 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 0732-183X (print) |
DOI: | 10.1200/JCO.22.01816 |
Sonstiges: |
|